[Clinical analysis of therapeutic effect of zoledronic acid combined with radiotherapy for metastatic bone cancer].
OBJECTIVE
To evaluate the efficacy of zoledronic acid combined with local radiotherapy for limited metastatic bone cancer.


METHODS
Forty-five patients with limited bone metastatic cancers were randomly divided into two groups: 23 in the combination group who received intravenously administration of zoledronic acid and local radiotherapy, the other 22 in the radiotherapy alone group who underwent local radiotherapy only.


RESULTS
The response rate of pain relief was 91.3% in the combination group versus 86.4% in the radiotherapy alone group, without statistically significant difference between two groups (P > 0.05). However, the recalcification rate was significantly higher in the combination therapy group (52.2%) than that in radiotherapy alone group (22.7% P < 0.01), and the proportion of patients with new bone metastasis formation was significantly lower in the combination group (13.0%) than that in the radiotherapy alone group (40.9%, P < 0.05). The common side-effects were transient pyrexia and nausea.


CONCLUSIONS
Zoledronic acid combined with local radiotherapy is effective in relieving pain, improving bone recalcification and reducing the formation of new bone metastasis.
Cheng
Jing
J
Department of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China. chenjin1118@hotmail.com
Xue
Jun
J
Wu
Hong-Ge
HG
Wu
Gang
G
D000328:Adult; D000368:Aged; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D001861:Bone Regeneration / Q000187:drug effects; D001943:Breast Neoplasms / Q000473:pathology; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000473:pathology; D010146:Pain / Q000209:etiology; D059408:Pain Management; D011878:Radiotherapy; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid